News for FibroGen, Inc. (FGEN.MX)

**media[653542]**

FibroGen (FGEN) has appointed Dr. Michael Kauffman to its Board of Directors, effective June 4, 2025. Dr. Kauffman brings 30 years of life sciences industry

vTv Therapeutics (VTVT) has appointed Michael Tung, M.D., MBA, as Executive Vice President and Chief Financial Officer. The company has reinitiated its

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. ( VTVT), a late-stage biopharmaceutical company, today announced the appointment of M

Total Revenue: $2.7 million for Q1 2025, compared to $25.4 million for Q1 2024.Operating Costs and Expenses: $17.7 million for Q1 2025, a decrease of 76% from

May 12, 2025 / 09:00PM GMTOperator Good day, and thank you for standing by. Welcome to FibroGen first quarter 2025 earnings conference call. (Operator Instructi

FibroGen expects to enhance its financial position by selling FibroGen China for up to $185 million. Wall Street analysts predict significant potential

FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ETCompany ParticipantsJoanne Greller - LifeSci AdvisorsThane Wettig -...

Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance N

Revenue: $2.7 million for Q1 2025, surpassing the estimated $2.00 million.Net Loss: $16.8 million from continuing operations, significantly reduced from $49.0

FibroGen is set to announce its first-quarter earnings soon, with analysts expecting significant revenue declines. Current analyst price targets suggest

SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. ( FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. ( FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual He

FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of

Total Revenue (Q4 2024): $3.1 million, down from $3.6 million in Q4 2023.Total Revenue (Full Year 2024): $29.6 million, down from $46.8 million in 2023.Develop

Mar 17, 2025 / 09:00PM GMTOperator Hello, everyone, and welcome to the FibroGen fourth quarter and full year 2024 earnings conference call. (Operator Instructio

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ETCompany ParticipantsJoanne Greller - LifeSci AdvisorsThane Wettig -...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close o

Revenue: $3.1 million for Q4 2024, falling short of the estimated $24.91 million.Earnings Per Share (EPS): Reported a net loss of $0.08 per share, better than